Calibration and qc were within specifications.The customer correctly pretreated the samples with peg (polyethylene glycol) prior to testing.Testing results: (listed as: patient id: prl ii+peg (ng/ml), prl ii/c, peg/c).2: 33, 149%, 112%.3: 32, 143%,119%.4: 37.8, 172%, 147%.5: 28.2, 136%, 107%.6: 33.4, 139%, 121%.7: 26.6, 150%, 121%.8: 38.4, 141%, 139%.9: 24.8, 152%, 119%.14: 19.76, 132%, 101%.15: 22.4, 133%, 114%.17: 19.36, 154%, 127%.18: 29.4, 178%, 154%.19: 22, 131%, 100%.20: 31.8, 147%, 123%.21: 27, 131%, 76%.22: 40.6, 139%, 96%.23: 18.3, 146%, 90%.24: 27.2, 173%, 145%.26: 57.4, 144%, 121%.27: 25.2, 141%, 129%.29: 17.48, 144%, 107%.31: 19.32, 151%, 131%.32: 15.14, 172%, 123%.The investigation found that the samples are suspicious of containing high amounts of macro prolactin, for which the elecsys prl ii assay is more sensitive than the centaur/seimens platform.The customer pre-selected special patient samples and compared those to a competitor assay.This is suggested by high frequency of > reference range samples with low post-peg prl ii recovery the investigation concluded the measured values are correct.The investigation did not identify a product problem.
|